English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, July 14, 2020
エーザイとバイオジェン、BAN2401についてプレクリニカル(無症状期)アルツハイマー病を対象とした新たな臨床第III相試験(AHEAD 3-45)を開始
Eisai: Initiation of New Phase III Clinical Study (Ahead 3-45) of ban2401 Preclinical (Asymptomatic) Alzheimer's Disease
Monday, July 13, 2020
Eisai: Industry-Academia-Government Joint Development Agreement Aiming for Drug Discovery for Systemic Lupus Erythematosus by Practical Application of Toll-Like Receptor Research Concluded
Friday, July 10, 2020
エーザイ、Toll様受容体研究の実用化による全身性エリテマトーデス治療薬の創製をめざした産学官共同研究開発契約を締結し、研究活動を開始
Thursday, July 9, 2020
Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer's Disease
Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma
エーザイとMSD、切除不能肝細胞がんに対する一次療法としてのレンバチニブとペムブロリズマブの併用療法に関し、米国FDAより審査完了通知を受領
バイオジェンとエーザイ、アデュカヌマブについてアルツハイマー病治療薬として米国FDAへ生物製剤ライセンス申請完了
Wednesday, July 8, 2020
エーザイ、自社創製の新規不眠症治療薬「DAYVIGO(R)」が香港において新薬承認申請受理
Eisai: New Drug Application for In-House Developed New Anti-insomnia Drug Dayvigo Accepted in Hong Kong

Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575